These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 19027427

  • 1. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Kumar V, Ghosh B, Raina UK, Goel N.
    Am J Ophthalmol; 2008 Dec; 146(6):974; author reply 974-5. PubMed ID: 19027427
    [No Abstract] [Full Text] [Related]

  • 2. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, Nishida K.
    Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
    [Abstract] [Full Text] [Related]

  • 3. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
    Rensch F, Spandau UH, Wickenhäuser A, Jonas JB.
    Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
    [No Abstract] [Full Text] [Related]

  • 4. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
    Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R.
    Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A.
    Retina; 2006 Jan; 26(9):999-1005. PubMed ID: 17151486
    [Abstract] [Full Text] [Related]

  • 6. Comparison of a single intravitreal injection of bevacizumab versus triamcinolone acetonide as primary treatment for diffuse diabetic macular oedema.
    Penha FM, Maia M, Cardillo JA, Arevalo JF, Wu L, Rodriguez FJ, Berrocal MH, Farah ME, Pan-American Collaborative Retina Study.
    Acta Ophthalmol; 2012 Mar; 90(2):e160-1. PubMed ID: 21470386
    [No Abstract] [Full Text] [Related]

  • 7. Combined therapy with intravitreal bevacizumab and posterior subtenon triamcinolone acetonide injection in diabetic macular oedema.
    Kim HD, Kang KD, Choi KS, Rhee MR, Lee SJ.
    Acta Ophthalmol; 2014 Nov; 92(7):e589-90. PubMed ID: 24866832
    [No Abstract] [Full Text] [Related]

  • 8. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S, Rush R, Natarajan S, Gillies M.
    Clin Exp Ophthalmol; 2011 Nov; 39(7):673-81. PubMed ID: 22452685
    [Abstract] [Full Text] [Related]

  • 9. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
    Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Peyman GA.
    Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
    [Abstract] [Full Text] [Related]

  • 10. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema.
    Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I.
    Am J Ophthalmol; 2004 Jul; 138(1):158-60. PubMed ID: 15234306
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Diagnostic and therapeutic challenges.
    Dinç UA, Yenerel NM, Görgün E, Yetik H, Kokame GT, Lim JI.
    Retina; 2009 Feb; 29(2):275-9. PubMed ID: 18827730
    [No Abstract] [Full Text] [Related]

  • 13. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
    Sonoda Y, Arimura N, Shimura M, Sakamoto T.
    Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
    [Abstract] [Full Text] [Related]

  • 14. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.
    Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, Piri N, Faghihi Sh.
    Eur J Ophthalmol; 2008 Feb; 18(6):941-8. PubMed ID: 18988166
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Tabatabaei H, Peyman GA.
    Retina; 2007 Feb; 27(9):1187-95. PubMed ID: 18046223
    [Abstract] [Full Text] [Related]

  • 16. OCT and cataract.
    Falavarjani KG, Modarres M, Nikeghbali A.
    Ophthalmology; 2010 Apr; 117(4):849; author reply 849-50. PubMed ID: 20346827
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
    Akinci A, Muftuoglu O, Altınsoy A, Ozkılıc E.
    Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.